FDA 483 - Edge Pharma, LLC - March 30, 2020

An FDA inspection of Edge Pharma, LLC, an outsourcing facility in Colchester, VT, conducted from March 4-30, 2020, revealed 14 observations. William Chattoff, CEO, was issued the report.

Key violations include:

**Quality System and Manufacturing Issues:** * **Inadequate Investigations (Observation 1):** Failure to thoroughly investigate unexplained discrepancies, batch failures, and customer complaints. This includes recalled sterile drug products (e.g., mislabeled Neostigmine, Bevacizumab with subvisible particles, sub-potent Dibutyl Squaric Acid), presumptive sterility positives (e.g., Cefuroxime PF, Phenylephrine HCl, Media Fill contaminants, Cefuroxime PF), and 9 customer complaints regarding leaking/broken container closure systems. Previous inspections in 2018 also noted inadequate investigations. * **Environmental Monitoring Deficiencies (Observation 2):** Inadequate environmental monitoring practices in classified and aseptic processing areas. This includes failure to investigate environmental excursions with microbial species identification and perform corrective actions (e.g., mold in ISO-8 and ISO-7 rooms), incomplete identification of objectionable microorganisms (24 out of 294 mold/fungus recoveries not identified to species level), failure to identify/investigate all ISO-5 microbial recoveries from operator sleeves, unscientific sampling locations for laminar flow hoods, lack of scientific rationale for alert/action levels,